Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival

Gomez, Daniel R.; Liao, Kai; Swisher, Stephen G.; Blumenschein, George R.; Erasmus, Jeremy J.; Buchholz, Thomas A.; Giordano, Sharon H.; Smith, Benjamin D.

doi:10.1016/j.radonc.2015.04.010

Cited by 110 publications

(126 citation statements)

References 20 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…It was reported that a longer time interval between diagnosis and treatment was associated with shorter survival in breast cancer [5], uterine cancer, rectal cancer, bladder cancer, melanoma [7], and lung cancer patients [14]. However, a longer wait time was not related to the prognosis of esophageal cancer, gastric cancer, pancreatic cancer, colon cancer, renal cancer, or cervical cancer [7,15].…”

Section: Discussionmentioning

confidence: 99%

“…An increased time interval from diagnosis to treatment can be partly blamed on the pursuit of improved health care [18]. Other possible explanations include advancements in pretreatment work-up [14], referrals to high service volume institutes [18], shortages of therapeutic instruments and manpower [1,15], pending second opinions requested by the patients or doctor [15], and a lack of education and public awareness [1,20]. All told, the reasons for the increased time interval from diagnosis to treatment of OCSCC patients remain multifaceted, integrated, and poorly understood [21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study

et al. 2017

View full text Add to dashboard Cite

ObjectivesWe aimed to explore the relationship between the time interval from diagnosis to treatment and survival of oral cavity squamous cell carcinoma patients.Materials and methodsA population-based study was conducted between 2004 and 2010. Claims data of oral squamous cell carcinoma patients were retrieved from the Taiwan Cancer Registry Database. Secondary data were obtained from Taiwan’s National Health Insurance Research Database.ResultsA total of 21,263 patients were included in the final analysis. The majority of the patients received treatment within 30 days of diagnosis (n = 18,193, 85.5%), while 572 patients (2.7%) underwent treatment after 120 days. The patients who were treated after 120 days had a higher risk of death when compared to those treated within 30 days (Hazard ratio: 1.32, 95% Confidence intervals: 1.19 to 1.47).ConclusionA longer time interval from diagnosis to treatment was found to be associated with a poorer prognosis among patients suffering from oral squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…3,4 Although previous studies have investigated NSCLC outcomes, they tended to evaluate subgroups of patients, such as patients from specific regions, of specific ages, or who underwent surgery, or to focus on the effects of specific histological type or stage on survival. [5][6][7][8][9][10][11] In addition, accumulating evidence of significant racial and socioeconomic status (SES) disparities in the U.S. health care system has been attracting increased attention. We used period analysis in this study to demonstrate the shift in survival time in each decade between 1983 and 2012 and to determine the impacts of race, sex, age, and SES on the survival rates in patients with NSCLC, using data from the SEER program of the National Cancer Institute.…”

Section: Introductionmentioning

confidence: 99%

Survival improvement in patients with non–small cell lung cancer between 1983 and 2012: Analysis of the Surveillance, Epidemiology, and End Results database

Wang

Sun

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Non-small cell lung cancer is the most common malignancy in males; it constitutes the majority of lung cancer cases and requires massive medical resources. Despite improvements in managing non-small cell lung cancer, long-term survival remains very low. This study evaluated survival improvement in patients with non-small cell lung cancer in each decade between 1983 and 2012 to determine the impact of race, sex, age, and socioeconomic status on the survival rates in these patients. We extracted data on non-small cell lung cancer cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results registries. In total, 573,987 patients with non-small cell lung cancer were identified in 18 Surveillance, Epidemiology, and End Results registry regions during this period. The 12-month relative survival rates improved slightly across three decades, from 39.7% to 40.9% to 45.5%, with larger improvement in the last two decades. However, the 5-year-relative survival rates were very low, with 14.3%, 15.5%, and 18.4%, respectively, in three decades, indicating the urgency for novel comprehensive cancer care. In addition, our data demonstrated superiority in survival time among non-small cell lung cancer patients of lower socioeconomic status and White race. Although survival rates of non-small cell lung cancer patients have improved across the three decades, the 5-yearrelative survival rates remain very poor. In addition, widening survival disparities among the race, the sex, and various socioeconomic status groups were confirmed. This study will help in predicting future tendencies of incidence and survival of non-small cell lung cancer, will contribute to better clinical trials by balancing survival disparities, and will eventually improve the clinical management of non-small cell lung cancer.

show abstract

“…For patients who survived for at least 1 year, expedient treatment was associated with improved survival. [20]. Early detection of recurrence might allow for initiation of systemic therapy while patients have a good performance status.…”

Section: Discussionmentioning

confidence: 99%

Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non–small-cell Lung Cancer

Harandi

Daly

2017

Clinical Lung Cancer

View full text Add to dashboard Cite

Purpose/Objective(s) Uncertainty exists regarding the optimal surveillance imaging schedule following definitive chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) with regards to both frequency and modality. We sought to document the clinical impact of frequent (q≤4 month) surveillance imaging. Methods The records of all patients treated with CRT for stage IIIA/IIIB NSCLC between August 1999 and April 2014 were reviewed. Patients were included if they underwent frequent (Q≤4 month) chest computed tomography (CT) or positron emission tomography (PET/CT) for routine surveillance following CRT for at least one year or until progression or death. Radiographic findings and clinical interventions within the first year were identified. Results We identified 145 patients with LA-NSCLC treated with CRT, 63 with eligible imaging. Median age was 63.6 years (range, 41.0–86.9). Asymptomatic recurrence was radiographically detected in 38 (60.3%). Twenty-one (33.3%) initiated systemic therapy. Two (3.2%) underwent definitive-intent treatment for isolated disease, including lobectomy for a histologically-distinct primary NSCLC and stereotactic radiotherapy for an isolated recurrence, both of whom subsequently progressed. Eleven patients (17.5%) received no further therapy. Five patients (7.9%) underwent additional diagnostic procedures for false-positive findings. Conclusions Frequent surveillance within the first year following CRT for LA-NSCLC lung cancer detects asymptomatic recurrence in a high proportion of patients. However, definitive-intent interventions were infrequent. The predominant benefit of frequent surveillance appears to be expedient initiation of palliative systemic therapy. Evidence-based algorithms for surveillance are needed, and should account for expected patient tolerance of and willingness to undergo additional cancer-directed therapies.

show abstract

Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival

Cited by 110 publications

References 20 publications

Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study

Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study

Survival improvement in patients with non–small cell lung cancer between 1983 and 2012: Analysis of the Surveillance, Epidemiology, and End Results database

Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non–small-cell Lung Cancer

Contact Info

Product

Resources

About